Key result
Novel 6-biomarker and clinical panel strongly predicts death or MI over 2.5 years.
Why the study?
Does simultaneous assessment of multiple protein biomarkers improve prediction of death or MI in patients with suspected coronary disease?
Case-Control (n=546)
Does simultaneous assessment of multiple protein biomarkers improve prediction of death or MI in patients with suspected coronary disease?
Simultaneous assessment of multiple protein biomarkers identified a specific 6-biomarker panel that, along with clinical variables, is strongly associated with long-term risk of death or MI in patients with suspected coronary disease.
BACKGROUND: Although individual protein biomarkers are associated with cardiovascular risk, rarely have multiple proteins been considered simultaneously to identify which set of proteins best predicts risk. METHODS AND RESULTS: In a nested case-control study of 273 death/myocardial infarction (MI) cases and 273 age- (within 10 years), sex-, and race-matched and event-free controls from among 2023 consecutive patients (median follow-up 2.5 years) with suspected coronary disease, plasma levels of 53 previously reported biomarkers of cardiovascular risk were determined in a core laboratory. Three penalized logistic regression models were fit using the elastic net to identify panels of proteins independently associated with death/MI: proteins alone (Model 1); proteins in a model constrained to retain clinical variables (Model 2); and proteins and clinical variables available for selection (Model 3). Model 1 identified 6 biomarkers strongly associated with death/MI: intercellular adhesion molecule-1, matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2. In Model 2, only soluble CD40 ligand remained strongly associated with death/MI when all clinical risk predictors were retained. Model 3 identified a set of 6 biomarkers (intercellular adhesion molecule-1, matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clinical variables (age, red-cell distribution width, diabetes mellitus, hemoglobin, and New York Heart Association class) strongly associated with death/MI. CONCLUSIONS: Simultaneously assessing the association between multiple putative protein biomarkers of cardiovascular risk and clinical outcomes is useful in identifying relevant biomarker panels for further assessment.
No takes yet. Share an insight, caveat, or question.
Halim et al. (2014) conducted a case-control in suspected coronary disease (n=546). Simultaneous assessment of 53 candidate protein biomarkers was evaluated on death/myocardial infarction (MI). Simultaneous assessment of 53 candidate protein biomarkers identified a panel of 6 biomarkers and 5 clinical variables strongly associated with death or myocardial infarction over 2.5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: